The ALNEV.PA stock opened the EURONEXT pre-market session at EUR 0.0014 and is trading at EUR 0.0013, down -13.33% as of 06 Mar 2026. Heavy turnover is visible with 19,674,747 shares traded today versus an average of 11,663,971. The drop places Neovacs S.A. among the top losers in Europe’s healthcare names this morning and raises fresh liquidity and valuation questions for investors watching a biotech with a small market cap and negative EPS.

ALNEV.PA stock: pre-market price action and volume

Neovacs S.A. (ALNEV.PA) opened at EUR 0.0014 and slid to EUR 0.0013 in pre-market trade on 06 Mar 2026. The one-day move is -13.33% and intraday range is EUR 0.0012–0.0015.

Trading volume is elevated at 19,674,747 shares, about 1.69x the average volume, signalling a sharper sell bias than usual for this name on EURONEXT.

Fundamentals and valuation snapshot

Neovacs shows a market cap of EUR 620.00 and reported EPS -221.36, with no meaningful P/E due to negative earnings. Book value per share is reported as EUR 103.50, which reflects accounting items against a tiny free float and 476,625 shares outstanding.

Price averages are weak: 50-day average EUR 0.004374 and 200-day average EUR 0.67495, highlighting long-term declines. Current ratios and cash metrics point to funding risk: current ratio 0.63 and cash per share EUR 2.50.

Technical picture and liquidity risks

Technical indicators show extreme oversold signals: RSI 15.64 and CCI -196.90, while trend strength registers ADX 67.33. These readings suggest a strong downtrend with short-term exhaustion.

Liquidity remains mixed: average volume 11,663,971, today 19,674,747, and on‑book metrics like OBV are deeply negative. Tight bid layers and wide spreads are likely, increasing execution risk for large orders.

Meyka AI grade and model forecast for ALNEV.PA stock

Meyka AI rates ALNEV.PA with a score of 62.14 out of 100 — Grade B: HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts and analyst consensus.

Meyka AI’s forecast model projects EUR 0.04 (monthly) versus the current price EUR 0.0013, implying an upside of 2,976.92%. Forecasts are model-based projections and not guarantees. See our full price outlook and methodology on the Meyka platform: Neovacs on Meyka.

Sector context: healthcare and biotech comparison

Within Healthcare and Biotechnology on Europe exchanges, average PE sits near 30.6 and average current ratio about 2.17, both well above Neovacs’ metrics. Sector performance shows modest recent gains while Neovacs is a top loser.

Biotech names trade on development milestones; Neovacs’ Kinoid pipeline keeps clinical risk front and centre. Relative to peers, ALNEV.PA shows weaker liquidity and a more negative earnings profile.

Trading considerations, price targets and risks

Short-term traders may target a mechanical bounce to EUR 0.0020 (implied upside +53.85%) while a conservative downside scenario sits near EUR 0.0010 (implied -23.08%). A 12‑month base case target of EUR 0.05 is scenario-driven and assumes positive clinical news or a capital raise.

Key risks: funding dilution, continued negative EPS, and low float dynamics. Near-term catalysts to watch are regulatory updates, cash runway disclosures, and any clinical trial announcements.

Final Thoughts

ALNEV.PA stock is trading as one of the morning’s top losers on EURONEXT after a -13.33% pre-market move to EUR 0.0013 on 06 Mar 2026. Elevated volume and oversold technicals create the potential for short-term bounces, but fundamentals remain weak: EPS -221.36, current ratio 0.63, and minimal market cap EUR 620.00. Meyka AI assigns a B (62.14/100) grade and presents a model forecast of EUR 0.04 (monthly), implying a large model-based upside of 2,976.92% versus the current price; this is illustrative, not guaranteed. For investors, the trade-off is clear: potential high-reward scenarios depend on binary biotech catalysts and funding clarity, while downside risks include dilution and persistent negative earnings. Monitor cash disclosures, clinical updates and liquidity conditions before increasing exposure to this high-volatility, small-cap biotech.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.